Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
11 hedge funds and large institutions have $151K invested in Sonnet BioTherapeutics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
10% more funds holding
Funds holding: 10 → 11 (+1)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.02% less ownership
Funds ownership: 0.03% → 0.01% (-0.02%)
61% less capital invested
Capital invested by funds: $389K → $151K (-$238K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$19.9K |
| 2 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$11.6K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$7.44K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.35K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$144K |
| 2 |
VF
Virtu Financial
New York
|
-$40K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$28K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
-$2.19K |
SONN Hedge Fund Activity: Q4 2022 in Review
11 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q4 2022, worth a combined $151K — down 61% from $389K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SONN positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 3 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $19.9K. The largest seller was Vanguard Group, cutting an estimated $144K.
- 11 institutional investors held Sonnet BioTherapeutics (SONN) as of Q4 2022, up from 10 in Q3 2022.
- Funds reported $151K of Sonnet BioTherapeutics stock for Q4 2022, down 61% quarter-over-quarter.
- 3 funds opened new Sonnet BioTherapeutics positions in Q4 2022 and 2 closed out, a net change of +1 holder.
- The largest Sonnet BioTherapeutics buyer in Q4 2022 was HRT Financial, an estimated $19.9K added.
- The largest Sonnet BioTherapeutics seller in Q4 2022 was Vanguard Group, an estimated $144K sold.
Based on aggregated 13F filings for Q4 2022.